Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.92
NVGN's Cash to Debt is ranked higher than
67% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. NVGN: 0.92 )
NVGN' s 10-Year Cash to Debt Range
Min: 0.92   Max: No Debt
Current: 0.92

Equity to Asset 0.32
NVGN's Equity to Asset is ranked higher than
52% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. NVGN: 0.32 )
NVGN' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.86
Current: 0.32

0.32
0.86
F-Score: 2
Z-Score: -41.34
M-Score: -7.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7650.57
NVGN's Operating margin (%) is ranked lower than
54% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.26 vs. NVGN: -7650.57 )
NVGN' s 10-Year Operating margin (%) Range
Min: -7650.57   Max: -31.89
Current: -7650.57

-7650.57
-31.89
Net-margin (%) -8583.91
NVGN's Net-margin (%) is ranked lower than
54% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.01 vs. NVGN: -8583.91 )
NVGN' s 10-Year Net-margin (%) Range
Min: -8583.91   Max: 90.46
Current: -8583.91

-8583.91
90.46
ROE (%) -216.46
NVGN's ROE (%) is ranked lower than
54% of the 894 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. NVGN: -216.46 )
NVGN' s 10-Year ROE (%) Range
Min: -269.02   Max: 33.98
Current: -216.46

-269.02
33.98
ROA (%) -116.38
NVGN's ROA (%) is ranked lower than
54% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.27 vs. NVGN: -116.38 )
NVGN' s 10-Year ROA (%) Range
Min: -143.49   Max: 12.06
Current: -116.38

-143.49
12.06
ROC (Joel Greenblatt) (%) -12250.31
NVGN's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.87 vs. NVGN: -12250.31 )
NVGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9309.09   Max: -69.26
Current: -12250.31

-9309.09
-69.26
Revenue Growth (3Y)(%) -100.00
NVGN's Revenue Growth (3Y)(%) is ranked lower than
52% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. NVGN: -100.00 )
NVGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 2
Current: -100

-100
2
EBITDA Growth (3Y)(%) -28.60
NVGN's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. NVGN: -28.60 )
NVGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.3   Max: 31.5
Current: -28.6

-65.3
31.5
EPS Growth (3Y)(%) -14.50
NVGN's EPS Growth (3Y)(%) is ranked higher than
65% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.30 vs. NVGN: -14.50 )
NVGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.5   Max: 24.1
Current: -14.5

-62.5
24.1
» NVGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NVGN Guru Trades in

NVGN Guru Trades in

Q2 2013

NVGN Guru Trades in Q2 2013

Jim Simons 15,240 sh (-66.09%)
» More
Q3 2013

NVGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 18.10
NVGN's P/B is ranked lower than
55% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. NVGN: 18.10 )
NVGN' s 10-Year P/B Range
Min: 0.95   Max: 13.11
Current: 18.1

0.95
13.11
EV-to-EBIT -4.83
NVGN's EV-to-EBIT is ranked higher than
59% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.80 vs. NVGN: -4.83 )
NVGN' s 10-Year EV-to-EBIT Range
Min: -44   Max: 0.2
Current: -4.83

-44
0.2
Current Ratio 0.81
NVGN's Current Ratio is ranked lower than
53% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. NVGN: 0.81 )
NVGN' s 10-Year Current Ratio Range
Min: 0.81   Max: 9.78
Current: 0.81

0.81
9.78
Quick Ratio 0.81
NVGN's Quick Ratio is ranked higher than
52% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. NVGN: 0.81 )
NVGN' s 10-Year Quick Ratio Range
Min: 0.81   Max: 8.68
Current: 0.81

0.81
8.68
Days Sales Outstanding 289.48
NVGN's Days Sales Outstanding is ranked higher than
56% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 78.61 vs. NVGN: 289.48 )
NVGN' s 10-Year Days Sales Outstanding Range
Min: 1.51   Max: 404.33
Current: 289.48

1.51
404.33

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.50
NVGN's Price/Tangible Book is ranked higher than
56% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NVGN: 9.50 )
NVGN' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 19.5
Current: 9.5

1.5
19.5
Earnings Yield (Greenblatt) -21.70
NVGN's Earnings Yield (Greenblatt) is ranked lower than
54% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. NVGN: -21.70 )
NVGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 652.6   Max: 4548.1
Current: -21.7

652.6
4548.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NRT.Australia, NV9.Germany, NV9B.Germany,
Novogen Ltd
» More Articles for NVGN

Headlines

Articles On GuruFocus.com
Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 
comment on NVGN Mar 06 2013 

More From Other Websites
Novogen shares surge on drug data Mar 30 2015
4:44 am Novogen and Yale University release data on Cantrixil mode of action Mar 30 2015
Yale University and Novogen Release Data on Cantrixil Mode of Action Mar 29 2015
Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study Mar 18 2015
Sky News, Helen Dalley interviews Dr Graham Kelly Mar 09 2015
Cantrixil Data to be Presented at Two Major Conferences Mar 06 2015
Novogen Makes Big Step In Fighting Brain Cancer Mar 04 2015
US Studies Confirm Ability of TRXE-009 to Kill Brain Cancer Stem Cells Mar 04 2015
Novogen to Present at AusBiotech "Broker Meets Biotech" Event Mar 02 2015
Novogen to Present at SACHS Cancer Bio Partnering & Investment Forum Feb 22 2015
Novogen Investor Briefing Well Received Feb 19 2015
Novogen Lodges Key Super-benzopyran Patent Feb 11 2015
Novogen to present at BIO & CEO Investor Conference 9th & 10th February, 2015 Feb 03 2015
Novogen Soars 50% Following Brain Stem Cell News Jan 15 2015
Novogen Announces Important Discovery in Regenerative Medicine Program Jan 15 2015
Novogen to Conduct Shareholder/Investor Briefing in New York Jan 07 2015
Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private... Dec 19 2014
Novogen Raises A$4.1m In Private Placement to US Institutions Dec 17 2014
Novogen Announces Breakthrough Discovery in the Treatment of Melanoma Dec 16 2014
Novogen Shares Skyrocket 120% Following Drug News Dec 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK